AstraZeneca's asthma drug Tezspire succeeds in late-stage esophagitis trial
- Posted on August 27, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
AstraZeneca's asthma drug Tezspire succeeds in late-stage esophagitis trial
Aug 27 (Reuters) - AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen, met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus. The study showed Tezspire when compared with a placebo managed to significantly reduce inflammation in the esophagus, and also ease the frequency and
